Fig. 1
a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab
Fig. 1 | British Journal of Cancer
a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab
